Back to news

Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

Globe Newswire•15/11/2026•07:00 ET
22

Key Highlights

  • ➤CDI-988 Phase 1b challenge study completed dosing with no serious adverse events reported
  • ➤Preliminary CDI-988 efficacy results expected near the end of 2026
  • ➤OPKO Health invested $5.0 million in Cocrystal through a private placement
  • ➤Q3 net loss widened to $3.444 million from $2.049 million year over year
  • ➤Cash totaled $4.873 million and working capital $2.311 million at September 30

Expert Statements

James Sapirstein, Chief Executive Officer of Cocrystal Pharma

“Dosing the last subject in our Phase 1b challenge study brings Cocrystal to a key value inflection point. With the continued support of OPKO Health and a board strengthened by Dr. Brosgart’s antiviral development experience, we are focused on reporting preliminary efficacy data from CDI-988 during late 2026 and positioning the program for its next stage of clinical development”

Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health; co-founder, director and principal stockholder of Cocrystal

“The preliminary efficacy results will be an important test of what CDI-988 can do. OPKO increased its investment this quarter because norovirus represents both a substantial global need and an equally substantial commercial opportunity, and we believe CDI-988 has the potential to address both”

Sam Lee, Ph.D., President and Chief Scientific Officer of Cocrystal

“The study design lets us evaluate CDI-988 in both prevention and treatment settings, and completing dosing is an important step for the program. With no approved treatments or vaccines for norovirus, we look forward to efficacy data that will guide CDI-988’s path toward later-stage development”

* Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reported * Preliminary efficacy results expected near the end of 2026 * Closed $5 million private placement with OPKO Health * Appointed antiviral drug development leader Carol Brosgart, MD, to the Board of Directors BOTHELL, Wash., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities and reports financial results for the three and nine months ended September 30, 2026.

“Dosing the last subject in our Phase 1b challenge study brings Cocrystal to a key value inflection point. With the continued support of OPKO Health and a board strengthened by Dr. Brosgart’s antiviral development experience, we are focused on reporting preliminary efficacy data from CDI-988 during late 2026 and positioning the program for its next stage of clinical development,” said James Sapirstein, Chief Executive Officer of Cocrystal.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in